Development of a conjunctival contact–type drug delivery device for latanoprost using hyaluronic acid
Effective topical drug delivery is crucial for glaucoma treatment, necessitating more convenient methods to enhance patient compliance. This study evaluates the efficacy and safety of using freeze-dried hyaluronic acid (HA) as a carrier for a novel conjunctival-contact drug delivery system. We devel...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Drug Delivery |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/10717544.2025.2459775 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540900179312640 |
|---|---|
| author | Soomin Lee Mi-Young Jung Choul Yong Park |
| author_facet | Soomin Lee Mi-Young Jung Choul Yong Park |
| author_sort | Soomin Lee |
| collection | DOAJ |
| description | Effective topical drug delivery is crucial for glaucoma treatment, necessitating more convenient methods to enhance patient compliance. This study evaluates the efficacy and safety of using freeze-dried hyaluronic acid (HA) as a carrier for a novel conjunctival-contact drug delivery system. We developed HA tablets loaded with latanoprost (HA-latanoprost) and verified the concentration using high-performance liquid chromatography. Twenty mice (C57BL6) were divided into four groups (n = 5 per group): normal saline (group 1), control HA tablet (group 2), Xalatan™ (group 3), and HA-latanoprost tablet (group 4). Treatments were administered to the right eyes, with the left eyes serving as no-treatment controls. Intraocular pressure (IOP) and irritation (measured by scratching motions) were monitored for 10 days. On day 10, we quantified gene expression of inflammatory cytokines and IOP-affecting proteins using polymerase chain reaction, and performed histological and immunohistochemical analyses. Results showed that IOP was significantly lower in groups 3 and 4 compared to the other groups, with group 4 exhibiting the greatest reduction by day 10. Group 4 also experienced less irritation. Additionally, group 4 had lower expression of inflammatory cytokine genes and higher expression of IOP-lowering protein genes compared to group 3. No significant side effects were observed in any group. Overall, HA-latanoprost effectively lowered IOP and reduced ocular irritation more than latanoprost eyedrops in mice. However, these results are based on animal testing, so further development is needed for clinical use. |
| format | Article |
| id | doaj-art-730a03745e044844a3a2d5a3708fb9f4 |
| institution | Kabale University |
| issn | 1071-7544 1521-0464 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Drug Delivery |
| spelling | doaj-art-730a03745e044844a3a2d5a3708fb9f42025-02-04T12:23:10ZengTaylor & Francis GroupDrug Delivery1071-75441521-04642025-12-0132110.1080/10717544.2025.2459775Development of a conjunctival contact–type drug delivery device for latanoprost using hyaluronic acidSoomin Lee0Mi-Young Jung1Choul Yong Park2Department of Ophthalmology, Dongguk University Ilsan Hospital, Seoul, Republic of KoreaDepartment of Ophthalmology, Dongguk University Ilsan Hospital, Seoul, Republic of KoreaDepartment of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaEffective topical drug delivery is crucial for glaucoma treatment, necessitating more convenient methods to enhance patient compliance. This study evaluates the efficacy and safety of using freeze-dried hyaluronic acid (HA) as a carrier for a novel conjunctival-contact drug delivery system. We developed HA tablets loaded with latanoprost (HA-latanoprost) and verified the concentration using high-performance liquid chromatography. Twenty mice (C57BL6) were divided into four groups (n = 5 per group): normal saline (group 1), control HA tablet (group 2), Xalatan™ (group 3), and HA-latanoprost tablet (group 4). Treatments were administered to the right eyes, with the left eyes serving as no-treatment controls. Intraocular pressure (IOP) and irritation (measured by scratching motions) were monitored for 10 days. On day 10, we quantified gene expression of inflammatory cytokines and IOP-affecting proteins using polymerase chain reaction, and performed histological and immunohistochemical analyses. Results showed that IOP was significantly lower in groups 3 and 4 compared to the other groups, with group 4 exhibiting the greatest reduction by day 10. Group 4 also experienced less irritation. Additionally, group 4 had lower expression of inflammatory cytokine genes and higher expression of IOP-lowering protein genes compared to group 3. No significant side effects were observed in any group. Overall, HA-latanoprost effectively lowered IOP and reduced ocular irritation more than latanoprost eyedrops in mice. However, these results are based on animal testing, so further development is needed for clinical use.https://www.tandfonline.com/doi/10.1080/10717544.2025.2459775Hyaluronic acidconjunctivalatanoprostglaucomacontact |
| spellingShingle | Soomin Lee Mi-Young Jung Choul Yong Park Development of a conjunctival contact–type drug delivery device for latanoprost using hyaluronic acid Drug Delivery Hyaluronic acid conjunctiva latanoprost glaucoma contact |
| title | Development of a conjunctival contact–type drug delivery device for latanoprost using hyaluronic acid |
| title_full | Development of a conjunctival contact–type drug delivery device for latanoprost using hyaluronic acid |
| title_fullStr | Development of a conjunctival contact–type drug delivery device for latanoprost using hyaluronic acid |
| title_full_unstemmed | Development of a conjunctival contact–type drug delivery device for latanoprost using hyaluronic acid |
| title_short | Development of a conjunctival contact–type drug delivery device for latanoprost using hyaluronic acid |
| title_sort | development of a conjunctival contact type drug delivery device for latanoprost using hyaluronic acid |
| topic | Hyaluronic acid conjunctiva latanoprost glaucoma contact |
| url | https://www.tandfonline.com/doi/10.1080/10717544.2025.2459775 |
| work_keys_str_mv | AT soominlee developmentofaconjunctivalcontacttypedrugdeliverydeviceforlatanoprostusinghyaluronicacid AT miyoungjung developmentofaconjunctivalcontacttypedrugdeliverydeviceforlatanoprostusinghyaluronicacid AT choulyongpark developmentofaconjunctivalcontacttypedrugdeliverydeviceforlatanoprostusinghyaluronicacid |